159 related articles for article (PubMed ID: 35675209)
1. Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras.
Yu X; Cheng M; Lu K; Shen Y; Zhong Y; Liu J; Xiong Y; Jin J
J Med Chem; 2022 Jun; 65(12):8416-8443. PubMed ID: 35675209
[TBL] [Abstract][Full Text] [Related]
2. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC).
Zhang H; Zhao HY; Xi XX; Liu YJ; Xin M; Mao S; Zhang JJ; Lu AX; Zhang SQ
Eur J Med Chem; 2020 Mar; 189():112061. PubMed ID: 31951960
[TBL] [Abstract][Full Text] [Related]
4. The E3 ubiquitin ligase CHIP selectively regulates mutant epidermal growth factor receptor by ubiquitination and degradation.
Chung C; Yoo G; Kim T; Lee D; Lee CS; Cha HR; Park YH; Moon JY; Jung SS; Kim JO; Lee JC; Kim SY; Park HS; Park M; Park DI; Lim DS; Jang KW; Lee JE
Biochem Biophys Res Commun; 2016 Oct; 479(2):152-158. PubMed ID: 27475501
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686.
Li Q; Guo Q; Wang S; Wan S; Li Z; Zhang J; Wu X
Eur J Med Chem; 2022 Aug; 238():114455. PubMed ID: 35594654
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the development of EGFR degraders: PROTACs and LYTACs.
Hong D; Zhou B; Zhang B; Ren H; Zhu L; Zheng G; Ge M; Ge J
Eur J Med Chem; 2022 Sep; 239():114533. PubMed ID: 35728507
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent small molecule PROTACs targeting mutant EGFR.
Zhao HY; Yang XY; Lei H; Xi XX; Lu SM; Zhang JJ; Xin M; Zhang SQ
Eur J Med Chem; 2020 Dec; 208():112781. PubMed ID: 32883633
[TBL] [Abstract][Full Text] [Related]
8. HECT E3 ubiquitin ligase Nedd4-1 ubiquitinates ACK and regulates epidermal growth factor (EGF)-induced degradation of EGF receptor and ACK.
Lin Q; Wang J; Childress C; Sudol M; Carey DJ; Yang W
Mol Cell Biol; 2010 Mar; 30(6):1541-54. PubMed ID: 20086093
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
Cheng M; Yu X; Lu K; Xie L; Wang L; Meng F; Han X; Chen X; Liu J; Xiong Y; Jin J
J Med Chem; 2020 Feb; 63(3):1216-1232. PubMed ID: 31895569
[TBL] [Abstract][Full Text] [Related]
10. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands.
Cheng W; Li S; Han S; Miao R; Wang S; Liu C; Wei H; Tian X; Zhang X
Bioorg Med Chem; 2023 Mar; 82():117237. PubMed ID: 36906965
[TBL] [Abstract][Full Text] [Related]
12. Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells.
Mahan SD; Riching KM; Urh M; Daniels DL
Methods Mol Biol; 2021; 2365():151-171. PubMed ID: 34432243
[TBL] [Abstract][Full Text] [Related]
13. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
[TBL] [Abstract][Full Text] [Related]
14. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
Shi S; Du Y; Huang L; Cui J; Niu J; Xu Y; Zhu Q
Bioorg Chem; 2022 Mar; 120():105605. PubMed ID: 35081479
[TBL] [Abstract][Full Text] [Related]
16. E3 ligase ligand chemistries: from building blocks to protein degraders.
Sosič I; Bricelj A; Steinebach C
Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989
[TBL] [Abstract][Full Text] [Related]
17. Mathematical Model for Covalent Proteolysis Targeting Chimeras: Thermodynamics and Kinetics Underlying Catalytic Efficiency.
Chaudhry C
J Med Chem; 2023 May; 66(9):6239-6250. PubMed ID: 37102218
[TBL] [Abstract][Full Text] [Related]
18. Nano Proteolysis Targeting Chimeras (PROTACs) with Anti-Hook Effect for Tumor Therapy.
Zhang NY; Hou DY; Hu XJ; Liang JX; Wang MD; Song ZZ; Yi L; Wang ZJ; An HW; Xu W; Wang H
Angew Chem Int Ed Engl; 2023 Sep; 62(37):e202308049. PubMed ID: 37486792
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and activity study of a novel PI3K degradation by hijacking VHL E3 ubiquitin ligase.
Wang H; Li C; Liu X; Ma M
Bioorg Med Chem; 2022 May; 61():116707. PubMed ID: 35344835
[TBL] [Abstract][Full Text] [Related]
20. Discovery of highly potent and selective CRBN-recruiting EGFR
Zhang W; Li P; Sun S; Jia C; Yang N; Zhuang X; Zheng Z; Li S
Eur J Med Chem; 2022 Aug; 238():114509. PubMed ID: 35691176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]